Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Multiple Sclerosis 2Small Cell Lung Carcinoma 1Skin Neoplasms 1Multiple Sclerosis, Relapsing-Remitting 1Melanoma 1Lymphopenia 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Breast Neoplasms 1Astrocytoma 1

Interventions

fludarabine 4Cyclophosphamide 4Specimen Handling 2Nivolumab 2Natalizumab 2Interferon beta-1b 2Fingolimod Hydrochloride 2Blood Specimen Collection 2teriflunomide 1nabiximols 1gadobutrol 1gadobenic acid 1cabozantinib 1Surveys and Questionnaires 1Respiratory Therapy 1Registries 1Platinum Compounds 1Platelet Transfusion 1Plasma Exchange 1Phlebotomy 1OM 89 1Mn-PyC3A 1Medical Marijuana 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Ipilimumab 1Interferon beta-1a 1Injections 1Gadolinium DTPA 1Fish Oils 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Sclerosis × Fingolimod Hydrochloride × Clear all
NCT06705608 2024-11-26

MS; FTY720

University of British Columbia

Completed
4,000 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Multiple Sclerosis, Skin Neoplasms, Multiple Sclerosis, Relapsing-Remitting

NCT02939079 2019-05-14

Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients

Isfahan University of Medical Sciences

Phase 2/3 Completed
50 enrolled 20 charts

Multiple Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡